Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Gefitinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

TLK286 (Telcyta) HCl for Injection

gefitinib (Iressa)

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Telik

Gefitinib (Iressa)

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Open-Label Extension of Other SZ1839 (Iressa) Trials

Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.

AstraZeneca

Alison Armour Medical Science Director

Micronutrients

Hematinics

Vitamins

Pemetrexed

Mitogens

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

treatment of single pemetrexed with vitamin supplement until discontinued conditions are met

Pemetrexed (Alimta)

treatment of Gefitinib will be applied until discontinued conditions are met

Gefitinib (IRESSA)

This study is a prospective trial of Alimta (pemetrexed) versus IRESSA (gefitinib) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer (NSCLC) patients in a 2nd line setting.

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations

Chinese Society of Lung Cancer

Director of Chinese Society of Lung Cancer/Chief of Lung Cancer Research Institute & Cancer Center/Vice President of Guangdong General hospital

Symptoms and General Pathology

Nervous System Diseases

Rare Diseases

Adenocarcinoma

Neoplasm Metastasis

Adenocarcinoma of Lung

Brain Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Lung Adenocarcinoma

Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance

External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day

whole brain radiotherapy

Antoine CARPENTIER, MD,PhD

Multicentre randomised (1:1) trial assessing the efficacy of whole brain radiotherapy in addition to Gefitinib for the management of brain metastasis in lung cancer patients with a mutated EGFR.

Lung cancer patients with newly diagnosed CNS metastasis with- at least one brain lesion measuring \> 1 cm in longest dimension - not eligible for surgery or stereotactic radio-surgeryOpen-label, multicentre, national, randomised (1:1) phase II trialArm A: WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance Arm B: Gefitinib

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis

Randomized to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis

Ministry of Health, France

Assistance Publique - Hôpitaux de Paris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	NCT00080340	Non Small Cell ...	TLK286 (Telcyta... gefitinib (Ires...	18 Years -	Telik
Open-Label Extension of Other SZ1839 (Iressa) Trials	NCT00635973	Cancer	Gefitinib (Ires...	18 Years -	AstraZeneca
Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations	NCT00891579	Non Small Cell ...	Pemetrexed (Ali... Gefitinib (IRES...	18 Years - 80 Years	Chinese Society of Lung Cancer
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis	NCT01363557	EGFR-mutated Lu... Brain Metastasi...	whole brain rad... Gefitinib (IRES...	18 Years -	Assistance Publique - Hôpitaux de Paris
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis	NCT01363557	EGFR-mutated Lu... Brain Metastasi...	whole brain rad... Gefitinib (IRES...	18 Years -	Assistance Publique - Hôpitaux de Paris
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	NCT00080340	Non Small Cell ...	TLK286 (Telcyta... gefitinib (Ires...	18 Years -	Telik
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	NCT00080340	Non Small Cell ...	TLK286 (Telcyta... gefitinib (Ires...	18 Years -	Telik

Spots Global Cancer Trial Database for gefitinib (iressa)